Oxford Biomedica plc

    Jurisdiction
    United Kingdom
    LEI
    213800S1GVQNXQ15K851
    ISIN
    GB00BDFBVT43 (OXB.L)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    50 / 100
    Worse than peer group:
    52 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. Read full profile

    Fundamentals

    Net revenue
    €250.53M
    Gross margin
    42.3%
    EBIT
    -€261.30M
    EBIT margin
    -104.3%
    Net income
    -€230.27M
    Net margin
    -91.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €187.08M -25.3% -€31.39M -86.4%
    €246.76M +31.9% -€7.54M -76.0%
    €298.07M +20.8% €18.74M -348.6%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Add to watchlist

    Notifications